A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions

Healthy Participants

Interventions

DRUG

WD-910 tablet

Administered P.O.

DRUG

WD-910 Tablets Placebo

Administered P.O.

Trial Locations (1)

Nucleus Network Pty Ltd, Melbourne

All Listed Sponsors

lead

Zhejiang Wenda Medical Technology Co., Ltd.

OTHER